Product Datasheet

PepPool: SARS-CoV-2 (S1), scanning
Product code:3629-1

Contents:

The SARS-CoV-2 S1 scanning pool contains 166 peptides from the human
SARS-CoV-2 virus. The peptides are 15-mers overlapping with 11 aminoacids, covering the S1 domain of the spike protein (amino acid 13-685).
The pool is supplied in two vials: pool 1 SARS-CoV-2 S1 peptides 1-83 (83peptides) and pool 2 SARS-CoV-2 S1 peptides 84-166 (83 peptides). The
mean purity of the synthetic peptides is 80%.

Applications:

The peptide pool is recommended for enumeration of cytokine secreting
T cells specific for the SARS-CoV-2 S1 protein with ELISpot/FluoroSpot.
The peptide pool has been validated using human PBMC from COVID-19
convalescent individuals previously PCR-confirmed as SARS-CoV-2 positive.
The peptides can also induce specific T-cell responses in splenocytes frommice immunized with SARS-CoV-2 spike protein.

Instructions:

Sterile handling is recommended. The SARS-CoV-2 S1 pools can either
be used separately or mixed. If used separately, dissolve the lyophilized
peptide pools by addition of 40 μl DMSO to each vial, then add 85 μl PBS.
If mixed, first add 40 μl DMSO to pool 1 and transfer the solution into pool
2, then add 85 μl PBS. The concentration of these stock solutions are 200
μg/ml of each peptide. Aliquote the pools and store at -20°C or below. Thisstock solution will have a concentration of 200 μg/ml of each peptide.
Dilute the stock solution 1:100 in cell culture medium to obtain 2 μg/mlof each peptide in the cell culture. Use the peptide pool in ELISpot andFluoroSpot assay for stimulation of 250,000 cells per well. Use the diluted
peptide solution fresh.

Storage:

Shipped at ambient temperature. Store frozen at -20°C or below uponreceipt. After reconstitution, store aliquotes at -20°C or below. We
recommend the aliquots not be refrozen after initial use.

Quantity:

Two vials (pool 1+2), 25 μg of each peptide

Note; for research use only.
Mabtech shall not be liable for the use or handling of the product or forconsequential, special, indirect or incidental damages therefrom.
Mabtech AB (Head Office)SwedenTel: +46 8 716 27 00
mabtech@mabtech.com

Updated on 2022-11-22

Mabtech, Inc.
USA
Tel: +1 513 871-4500
mabtech.usa@mabtech.com

CERTIFIED
ISO 9001

CERTIFIED
ISO 13485

Quality management systems

Medical devices
Quality management systems

Developed and manufactured by MABTECH AB, Sweden,
whose quality management system complies with thestandards ISO 9001:2015 & ISO 13485:2016.

www.mabtech.com

Peptides included in PepPool: SARS-CoV-2 (S1), scanning
Peptide123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354Sequence
Pool 1 (1-83)
SQCVNLTTRTQLPPANLTTRTQLPPAYTNSRTQLPPAYTNSFTRG
PPAYTNSFTRGVYYPTNSFTRGVYYPDKVFTRGVYYPDKVFRSSVYYPDKVFRSSVLHSTKVFRSSVLHSTQDLF
SSVLHSTQDLFLPFF
HSTQDLFLPFFSNVTDLFLPFFSNVTWFHAPFFSNVTWFHAIHVS
NVTWFHAIHVSGTNG
FHAIHVSGTNGTKRF
HVSGTNGTKRFDNPVTNGTKRFDNPVLPFNKRFDNPVLPFNDGVY
NPVLPFNDGVYFASTPFNDGVYFASTEKSNGVYFASTEKSNIIRGASTEKSNIIRGWIFGKSNIIRGWIFGTTLDIRGWIFGTTLDSKTQIFGTTLDSKTQSLLITLDSKTQSLLIVNNAKTQSLLIVNNATNVVLLIVNNATNVVIKVCNNATNVVIKVCEFQF
NVVIKVCEFQFCNDPKVCEFQFCNDPFLGVFQFCNDPFLGVYYHKNDPFLGVYYHKNNKSLGVYYHKNNKSWMESYHKNNKSWMESEFRVNKSWMESEFRVYSSAMESEFRVYSSANNCTFRVYSSANNCTFEYVSSANNCTFEYVSQPF
NCTFEYVSQPFLMDLEYVSQPFLMDLEGKQQPFLMDLEGKQGNFKMDLEGKQGNFKNLREGKQGNFKNLREFVFKNFKNLREFVFKNIDGLREFVFKNIDGYFKI
VFKNIDGYFKIYSKHIDGYFKIYSKHTPINFKIYSKHTPINLVRDSKHTPINLVRDLPQGPINLVRDLPQGFSAL
VRDLPQGFSALEPLVPQGFSALEPLVDLPISALEPLVDLPIGINIPLVDLPIGINITRFQPeptide

Sequence

575859606162636465666768697071727374757677787980818283RFQTLLALHRSYLTP
LLALHRSYLTPGDSSHRSYLTPGDSSSGWT
LTPGDSSSGWTAGAADSSSGWTAGAAAYYVGWTAGAAAYYVGYLQGAAAYYVGYLQPRTFYYVGYLQPRTFLLKYYLQPRTFLLKYNENG
RTFLLKYNENGTITDLKYNENGTITDAVDCENGTITDAVDCALDPITDAVDCALDPLSETVDCALDPLSETKCTLLDPLSETKCTLKSFTSETKCTLKSFTVEKGCTLKSFTVEKGIYQTSFTVEKGIYQTSNFREKGIYQTSNFRVQPTYQTSNFRVQPTESIVNFRVQPTESIVRFPNQPTESIVRFPNITNLSIVRFPNITNLCPFGFPNITNLCPFGEVFNTNLCPFGEVFNATRFPFGEVFNATRFASVYVFNATRFASVYAWNR

84858687888990919293949596979899100101102103104105106107108109

Pool 2 (84-166)
TRFASVYAWNRKRISSVYAWNRKRISNCVAWNRKRISNCVADYSVRISNCVADYSVLYNSCVADYSVLYNSASFSYSVLYNSASFSTFKCYNSASFSTFKCYGVSSFSTFKCYGVSPTKLFKCYGVSPTKLNDLCGVSPTKLNDLCFTNVTKLNDLCFTNVYADSDLCFTNVYADSFVIRTNVYADSFVIRGDEVADSFVIRGDEVRQIA
VIRGDEVRQIAPGQTDEVRQIAPGQTGKIAQIAPGQTGKIADYNYGQTGKIADYNYKLPDKIADYNYKLPDDFTGYNYKLPDDFTGCVIALPDDFTGCVIAWNSNFTGCVIAWNSNNLDSVIAWNSNNLDSKVGGNSNNLDSKVGGNYNYLDSKVGGNYNYLYRLVGGNYNYLYRLFRKSPeptide112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156
157
158
159160161
162163164165
166Sequence
RKSNLKPFERDISTELKPFERDISTEIYQAERDISTEIYQAGSTPSTEIYQAGSTPCNGVYQAGSTPCNGVEGFNSTPCNGVEGFNCYFPNGVEGFNCYFPLQSY
GFNCYFPLQSYGFQPYFPLQSYGFQPTNGVQSYGFQPTNGVGYQP
FQPTNGVGYQPYRVVNGVGYQPYRVVVLSFYQPYRVVVLSFELLHRVVVLSFELLHAPATLSFELLHAPATVCGPLLHAPATVCGPKKSTPATVCGPKKSTNLVKCGPKKSTNLVKNKCVKSTNLVKNKCVNFNFLVKNKCVNFNFNGLTKCVNFNFNGLTGTGVFNFNGLTGTGVLTESGLTGTGVLTESNKKFTGVLTESNKKFLPFQTESNKKFLPFQQFGRKKFLPFQQFGRDIAD
PFQQFGRDIADTTDA
FGRDIADTTDAVRDP
IADTTDAVRDPQTLETDAVRDPQTLEILDI
RDPQTLEILDITPCSTLEILDITPCSFGGVLDITPCSFGGVSVITPCSFGGVSVITPGTNGGVSVITPGTNTSNQ
VITPGTNTSNQVAVLGTNTSNQVAVLYQDVSNQVAVLYQDVNCTEAVLYQDVNCTEVPVAQDVNCTEVPVAIHADCTEVPVAIHADQLTP
PVAIHADQLTPTWRVHADQLTPTWRVYSTG
LTPTWRVYSTGSNVF
WRVYSTGSNVFQTRASTGSNVFQTRAGCLINVFQTRAGCLIGAEH
TRAGCLIGAEHVNNSCLIGAEHVNNSYECDAEHVNNSYECDIPIGNNSYECDIPIGAGICECDIPIGAGICASYQPIGAGICASYQTQTNGICASYQTQTNSPRRSYQTQTNSPRRAR